WO 99/59629 41 PCT/US99/11179

WE CLAIM:

- 1 1. A humanized antibody that specifically binds to VT2
- 2 and/or VT2 variant
- 1 2. A humanized antibody that specifically binds to the B
- 2 subunit of VT2 and/or the B subunit of VT2 variant.
- 1 3. The humanized antibody of claim 1 that neutralizes VT2
- 2 and/or VT2 variant.
- 1 4. The humanized antibody of claim 2 that neutralizes VT2
- 2 and/or VT2 variant.
- 1 5. A humanized antibody that is a humanized form of mouse
- 2 antibody VTml-1, the mouse antibody being characterized by a
- 3 light chain variable region shown in Fig. 1B and a heavy
- 4 chain variable region shown in Fig. 1A.
- 1 6. An antibody that competes with mouse antibody VTml-1 for
- 2 specific binding to VT2 and/or VT2 variant.
- 1 7. A humanized antibody of any of claims 1-6 comprising
- 2 complementarity determining regions from the mouse VTm1-1
- 3 antibody and heavy and light chain variable region
- 4 frameworks from the human GF4 antibody heavy and light chain
- frameworks, provided that at least one position selected
- from the group consisting of L49, H29, H30, H49 and H98, is
- 7 occupied by the amino acid present in the equivalent
- 8 position of the mouse VTm1-1 antibody heavy or light chain
- 9 variable region framework, which humanized antibody
- 10 specifically binds to verotoxin II with an affinity constant
- 11 between $10^7 \, \text{M}^{-1}$ and ten-fold the affinity of the mouse VTml-1
- 12 antibody.

WO 99/59629 PCT/US99/11179

- 1 8. The humanized antibody of claim 7, provided that each
- 2 position selected from the group consisting of L49, H29,
- 3 H30, H49 and H98 is occupied by the amino acid present in
- 4 the equivalent position of the mouse VTm1-1 antibody heavy
- 5 or light chain variable region framework.
- 1 9. The humanized antibody of claim 8, provided that at
- least one position selected from the group L3, L4, L19, L76,
- 3 L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an
- 4 amino acid present in the equivalent position of a human
- 5 antibody heavy or light chain consensus sequence.
- 1 10. The humanized antibody of claim 9, provided that each
- 2 position selected from the group L3, L4, L19, L76, L79, L85,
- 3 H1, H4, H5, H79, H89 and H93 is occupied by an amino acid
- 4 present in the equivalent position of a human antibody heavy
- 5 or light chain consensus sequence.
- 1 11. The humanized antibody of any of claims 1-6 comprising
- 2 a heavy chain variable region shown in Fig. 2A and a light
- 3 chain variable region shown in Fig. 2B provided that one or
- 4 more positions selected from the group consisting of L49,
- 5 H29, H30, H49, H98, L3, L4, L19, L76, L79, L85, H1, H4, H5,
- 6 H79, H89 and H93 may be substituted as shown in Tables 2 and
- 7 3.
- 1 12. The humanized antibody of any of claims 1-6, comprising
- 2 a heavy chain variable region shown in Fig. 2A and a light
- 3 chain variable region shown in Fig. 2B.

4

- 5 13. The humanized antibody of any of claims 1-6, comprising
- 6 a humanized heavy chain having at least 85% identity with
- 7 the humanized heavy chain shown in Fig. 2A and a humanized
- 8 light chain having at least 85% sequence identity with the
- 9 humanized light chain showing in Fig. 2B, provided that at
- 10 least one position selected from the group consisting of

- 1 L49, H29, H30, H49 and H98, is occupied by the amino acid
- 2 present in the equivalent position of the mouse VTml-1
- 3 antibody heavy or light chain variable region framework.
- 1 14. The humanized antibody of any of claims 1-6, wherein
- 2 the antibody comprises two pairs of light/heavy chain
- dimers, wherein each chain comprises a variable region and a
- 4 constant region.
- 1 15. The humanized antibody of any of claims 1-6, which is a
- 2 Fab fragment or a F(ab')_{2.}
- 1 16. The humanized antibody of any of claims 1-6 in purified
- 2 form.
- 1 17. The humanized antibody of any of claims 1-6, which has
- 2 an IgG₁ immunoglobulin isotype.
- 1 18. A method of producing humanized VTml-1 antibody,
- 2 comprising culturing a cell line, which encodes heavy and
- 3 light chain chains of the humanized antibody of any of
- 4 claims 1-6, whereby the humanized antibody is expressed; and
- 5 recovering the humanized antibody expressed by the cell
- 6 line.
- 1 19. The method of claim 18, further comprising mixing the
- 2 antibody with a pharmaceutically acceptable carrier to
- 3 produce a pharmaceutical composition.
- 1 20. A pharmaceutical composition comprising the humanized
- 2 antibody of any of claims 1-6 and a pharmaceutically
- 3 acceptable carrier.
- 1 21. A pharmaceutical composition comprising the humanized
- 2 antibody of claim 12 and a pharmaceutically acceptable
- 3 carrier.

- 1 22. A method of treating a patient suffering or at risk of
- 2 toxic effects from a verotoxin, comprising administering to
- 3 the patient an effective dosage of a human or humanized
- 4 antibody that specifically binds to verotoxin II and/or
- 5 verotoxin II variant.
- 1 23. The method of claim 22, wherein the antibody competes
- 2 with mouse antibody VTml-1 for specific binding to verotoxin
- 3 II or verotoxin II variant.
- 1 24. The method of claim 22, wherein the humanized antibody
- 2 specifically binds to VT2 and/or VT2 variant.
- 1 25. The method of claim 22, wherein the humanized antibody
- 2 specifically binds to the B subunit of VT2 and/or VT2
- 3 variant.
- 1 26. The method of claim 22, wherein the humanized antibody
- 2 specifically binds to VT2 and/or VT2 variant and neutralizes
- 3 VT2 and/or VT2 variant.
- 4
- 5 27. The method of claim 22, wherein the humanized antibody
- 6 specifically binds to the B subunit of VT2 and/or the B
- 7 subunit of VT2 variant and neutralizes VT2 and/or VT2
- 8 variant.
- 1 28. The method of claim 22, wherein the antibody is a
- 2 humanized antibody, which is a humanized form of the mouse
- 3 VTm1-1 antibody.
- 1 29. The method of claim 22, wherein the antibody is a
- 2 humanized antibody comprising a heavy chain variable region
- 3 shown in Fig. 2A and a light chain variable region shown in
- 4 Fig. 2B.

WO 99/59629 PCT/US99/11179
45

- 1 30. The method of claim 22, wherein the patient is infected
- 2 with verotoxin producing E. coli and the antibody is
- 3 administered therapeutically.
- 1 31. The method of claim 22, wherein the patient is at risk
- of infection by verotoxin producing $E.\ coli$ and the antibody
- 3 is administered prophylactically.
- 1 32. The method of claim 30, further comprising monitoring
- 2 the patient for recovery from the toxic effects of verotoxin
- 3 II or verotoxin II variant.
- 1' 33. A cell line that produces the antibody of any of claim
- 2 1-6.